Trial Profile

Nateglinide: a double blind add-on study with pioglitazone for type 2 diabetic patients

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2006

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nateglinide (Primary) ; Pioglitazone
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

14 Dec 2006 Status change
11 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com